Cargando…
iRECIST and atypical patterns of response to immuno-oncology drugs
With the advent of immunotherapy as one of the keystones of the treatment of our patients with cancer, a number of atypical patterns of response to these agents has been identified. These include pseudoprogression, where the tumor initially shows objective growth before decreasing in size, and hyper...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9207898/ https://www.ncbi.nlm.nih.gov/pubmed/35715004 http://dx.doi.org/10.1136/jitc-2022-004849 |
_version_ | 1784729625720520704 |
---|---|
author | Ramon-Patino, Jorge Luis Schmid, Sabine Lau, Sally Seymour, Lesley Gaudreau, Pierre-Olivier Li, Janice Juan Ning Bradbury, Penelope Ann Calvo, Emiliano |
author_facet | Ramon-Patino, Jorge Luis Schmid, Sabine Lau, Sally Seymour, Lesley Gaudreau, Pierre-Olivier Li, Janice Juan Ning Bradbury, Penelope Ann Calvo, Emiliano |
author_sort | Ramon-Patino, Jorge Luis |
collection | PubMed |
description | With the advent of immunotherapy as one of the keystones of the treatment of our patients with cancer, a number of atypical patterns of response to these agents has been identified. These include pseudoprogression, where the tumor initially shows objective growth before decreasing in size, and hyperprogression, hypothesized to be a drug-induced acceleration of the tumor burden. Despite it being >10 years since the first immune-oncology drug was approved, neither the biology behind these paradoxical responses has been well understood, nor their incidence, identification criteria, predictive biomarkers, or clinical impact have been fully described. Immune-based Response Evaluation Criteria in Solid Tumors (iRECIST) guidelines have been published as a revision to the RECIST V.1.1 criteria for use in trials of immunotherapeutics, and the iRECIST subcommittee (of the RECIST Working Group) is working on elucidating these aspects, with data sharing a current major challenge to move forward with this unmet need in immuno-oncology. |
format | Online Article Text |
id | pubmed-9207898 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-92078982022-06-29 iRECIST and atypical patterns of response to immuno-oncology drugs Ramon-Patino, Jorge Luis Schmid, Sabine Lau, Sally Seymour, Lesley Gaudreau, Pierre-Olivier Li, Janice Juan Ning Bradbury, Penelope Ann Calvo, Emiliano J Immunother Cancer Review With the advent of immunotherapy as one of the keystones of the treatment of our patients with cancer, a number of atypical patterns of response to these agents has been identified. These include pseudoprogression, where the tumor initially shows objective growth before decreasing in size, and hyperprogression, hypothesized to be a drug-induced acceleration of the tumor burden. Despite it being >10 years since the first immune-oncology drug was approved, neither the biology behind these paradoxical responses has been well understood, nor their incidence, identification criteria, predictive biomarkers, or clinical impact have been fully described. Immune-based Response Evaluation Criteria in Solid Tumors (iRECIST) guidelines have been published as a revision to the RECIST V.1.1 criteria for use in trials of immunotherapeutics, and the iRECIST subcommittee (of the RECIST Working Group) is working on elucidating these aspects, with data sharing a current major challenge to move forward with this unmet need in immuno-oncology. BMJ Publishing Group 2022-06-16 /pmc/articles/PMC9207898/ /pubmed/35715004 http://dx.doi.org/10.1136/jitc-2022-004849 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Review Ramon-Patino, Jorge Luis Schmid, Sabine Lau, Sally Seymour, Lesley Gaudreau, Pierre-Olivier Li, Janice Juan Ning Bradbury, Penelope Ann Calvo, Emiliano iRECIST and atypical patterns of response to immuno-oncology drugs |
title | iRECIST and atypical patterns of response to immuno-oncology drugs |
title_full | iRECIST and atypical patterns of response to immuno-oncology drugs |
title_fullStr | iRECIST and atypical patterns of response to immuno-oncology drugs |
title_full_unstemmed | iRECIST and atypical patterns of response to immuno-oncology drugs |
title_short | iRECIST and atypical patterns of response to immuno-oncology drugs |
title_sort | irecist and atypical patterns of response to immuno-oncology drugs |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9207898/ https://www.ncbi.nlm.nih.gov/pubmed/35715004 http://dx.doi.org/10.1136/jitc-2022-004849 |
work_keys_str_mv | AT ramonpatinojorgeluis irecistandatypicalpatternsofresponsetoimmunooncologydrugs AT schmidsabine irecistandatypicalpatternsofresponsetoimmunooncologydrugs AT lausally irecistandatypicalpatternsofresponsetoimmunooncologydrugs AT seymourlesley irecistandatypicalpatternsofresponsetoimmunooncologydrugs AT gaudreaupierreolivier irecistandatypicalpatternsofresponsetoimmunooncologydrugs AT lijanicejuanning irecistandatypicalpatternsofresponsetoimmunooncologydrugs AT bradburypenelopeann irecistandatypicalpatternsofresponsetoimmunooncologydrugs AT calvoemiliano irecistandatypicalpatternsofresponsetoimmunooncologydrugs |